Patients with high expression of CX3CL1 had an ~2-fold increased risk of cancer-specific death based on univariable (HR=2.16, 95%CI: 1.59-2.93, P<0.001) and multivariable (HR=2.17, 95%CI: 1.08-2.39, P=0.006) analyses (Table 3). Here, CX3CL1 is linked to cancer.